Skip to main content
. 2022 Mar 17;12(3):461. doi: 10.3390/biom12030461

Figure 3.

Figure 3

NRF2 inhibition restores CDDP-induced p53 activity impaired by SFN. (a) NRF2-ctr and NRF2-Cas9 cells were treated with cisplatin (CDDP) (5 µg/mL) alone or in combination with SFN (2 µM) for 24 h before assessing the phospho (p) Ser46, p53 and HO-1 levels by Western blot. Actin was used as protein-loading control. Densitometric analysis of pSer46/p53, p53/β-actin and HO-1/β-actin is reported in the right panels. * p ≤ 0.01. (b) Total mRNA was extracted from NRF2-ctr and NRF2-Cas9 cells untreated or treated as in (a). The indicated gene expression was assayed by semiquantitative RT-PCR. The histograms represent the mean plus S.D. of three independent experiments. Densitometric analysis using ImageJ software was applied to calculate the gene/28S ratio. * p ≤ 0.01.